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ABSTRACT
A  novel  stability  indicating  reversed-phase  liquid  chromatographic method  has  been  developed  and  validated  for  simultaneous  estimation  of 
paroxetine and clonazepam in combined pharmaceutical dosage form. An Agilent zorbax sb-c18 (250mmx4.6mmx5 µm) column with the mobile 
phase  containing 0.2  % Orthophosphoric acid  and Methanol (60:40  v/v)  was  used.  The  flow  rate  was  maintained  at  0.8 ml/min,  column 
temperature  was  30°C  and  effluents  were  monitored  by  using  a  photodiode  array  detector  at 270  nm.  The  retention  times  of  paroxetine  and 
clonazepam were found to be 3.478min and 3.964 min, respectively. Correlation co-efficient for paroxetine and clonazepam were found to be 0.99 
and 0.99, respectively. The proposed method was validated with respect to linearity, accuracy, precision, specificity, and robustness. Recovery of 
paroxetine and clonazepam in formulations was found to be in a range of 97-103% and 97-103% respectively. Paroxetine and clonazepam were 
also subjected to the stress conditions of oxidative, acid, base, hydrolytic, thermal and photolytic degradation. The degradation products were well 
resolved from and peak purity test results confirmed that paroxetine and clonazepam peaks were homogenous and pure in all stress samples, thus
proving stability-indicating power of the method. Due to its simplicity, rapidness and high precision, this method can be applied for regular analysis.
Keywords: Paroxetine and clonazepam, Liquid chromatography, Method validation, Forced degradation. 
 
INTRODUCTION 
Paroxetine: (3S, 4R) -3- [(1, 3-benzodioxol-5-vloxy) methyl] -4- 
(4-flurophenyl) piperidine (PRX) is a new generation antidepressant 
drug[1]. It exerts its antidepressant effect through a selective 
inhibition for the reuptake of the neurotransmitter serotonin by the 
presynaptic receptors. PRX is comparable to the tricyclic 
antidepressants in their clinical efficacy, however, PRX is safer and 
has greater acceptance by the patients. It is also prescribed in the 
treatment of relateddisorders, suchasobsessive - compulsive 
Disorder, panic fits, social phobia, and posttraumatic stress2. 
Clonazepam (Merck Index, 13th edition, 2002, 2413) [5-(o-
chlorphenyl)-7-nitro-1H-1,4-benzodiazepin-2(3H)-one] is mainly 
used as anticonvulsant, muscle relaxant and anxiolytic agent. 
Clonazepam is slightly soluble in acetone, chloroform, acetic 
anhydride, hardly soluble in methanol, isopropanol, ether, almost 
insoluble in water. Chemical structures of paroxetine and 
clonazepam are presented in Figure I.  
   
Fig. 1: Structures of (A) Paroxetine and (B) Clonazepam 
A literature survey revealed few liquid chromatography (LC) assay 
methods that have been reported for the determination of 
clonazepam in bulk drug and pharmaceutical dosage forms, but 
there are no reported methods for simultaneous estimation of 
paroxetine and clonazepam in combined pharmaceutical dosage 
forms [3-13]. 
The present International Conference on Harmonization (ICH) drug 
stability guidelines suggest that stress studies should be conducted 
on the drug product to establish its inherent stability characteristics, 
and the analytical method should able to separate all degradation 
impurities formed under stress studies to prove its stability-
indicating power. In order to monitor possible changes to a product 
over time, the applied analytical chromatographic method must be 
stability-indicating. The best case for testing the suitability of a 
method is using real-time stability samples containing all relevant 
degradation products that might occur. But due to product 
development timelines, process characteristics, excipients, and other 
environmental factors, a forced degradation study (stress test) can 
serve as an alternative. 
 In a typical study, relevant stress conditions are light, heat, 
humidity, hydrolysis (acid / base influence) and oxidation or even a 
combination of described parameters. If it is necessary to form 
degradation products, the strength of stress conditions can vary due 
to the chemical structure of the drug substance, the kind of drug 
product, and product specific storage requirements. An individual 
program has to be set up in order to reach a target degradation of 5 
to 20%. A higher level of degradation will be out of the scope of 
product stability requirements and therefore unrealistic. The scope 
of the test is to generate degradation products in order to facilitate a 
method development for determination of the relevant products. 
Therefore, samples will be stressed in a solid form and/or in 
solution. Typically, stress tests are carried out on one batch of 
material. For drug products the placebo should be stressed in a 
similar way in order to exclude those impurities that are not 
degradation products (e.g. impurities arising from excipients). The 
stability studies were determined by applying the physical stress 
(acid, base, peroxide, heat and light) to the product [14-19].  
The aim of the present work is to focus on the development of an 
efficient stability indicating liquid chromatographic method for 
simultaneous estimation of paroxetine and clonazepam in combined 
pharmaceutical dosage form such as capsule in presence of its 
excipients and degradation products in a short chromatographic run. 
The present work concerns the method development, method 
validation and forced degradation studies of paroxetine and 
clonazepam in combined pharmaceutical dosage form. The developed 
Liquid Chromatographic method was validated with respect to 
specificity, limit of detection (LOD), limit of quantification (LOQ), 
linearity, precision, accuracy and robustness. Forced degradation 
studies were performed on the placebo and drug products to show the 
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stability-indicating nature of the method. These studies were 
performed in accordance with established ICH guidelines. 
Experimental  
Instrumentation 
Samples were analyzed on Waters alliance 2695 HPLC system 
(Waters Corporation, Milford, MA) equipped with a with binary 
HPLC pump, Waters 2998 PDA detector and Waters Empower 2.0 
software. The separation was achieved on Agilent zorbax sb-c18 
(250 mm x 4.6 mm x 5 µm) column.  
Chemicals and Reagents 
Paroxetine and Clonazepam standards were supplied by Dr. Reddy’s 
Laboratories Ltd., Hyderabad. Methanol of HPLC grade was 
purchased from E. Merck (India) Ltd., Mumbai. Orthophosphoric 
acid of AR grade was obtained from S.D. Fine Chemicals Ltd., 
Mumbai and milli Q water. Paroxetine and Clonazepam capsules 
(ZAPTRA 25 - Intas Company) were procured from Local market. 
 HPLC Conditions 
The mobile phase consisting of 0.2% v/v ortho phosphoric acid and 
methanol (HPLC grade) were filtered through 0.45 µm membrane filter 
before use, degassed and were pumped from the solvent reservoir in the 
ratio of 60:40 v/v into the column at a flow rate of 0.8 ml/min. The 
column temperature was maintained at 30°C. The detection was 
monitored at 270 nm and the run time was 6.0 minutes. The volume of 
injection loop was 10 µl prior to injection of the drug solution.  
 Preparation of standard solution  
Accurately weighed quantity, 100 mg of Paroxetine and 2 mg of 
Clonazepam was transferred into 50 ml of volumetric flask and 
diluted to the volume with mobile phase. From this stock, 5 ml of a 
solution was taken into a 10 ml volumetric flask and diluted to the 
volume with mobile phase (Concentration of Paroxetine: 1 mg/ml, 
concentartion of Clonazepam: 20µg/ml). 
Preparation of sample (drugs from marketed formulations) 
solution 
Twenty tablets were weighed and the average weight was calculated 
and crushed in to the fine powder, Tablet powder (Equivalent to 
four tablets) was transferred into 50 ml of volumetric flask and 
diluted to the volume with mobile phase. From this stock solution 5 
ml was transferred into a 10 ml volumetric flask and diluted to the 
volume with mobile phase.(Concentration of Paroxetine : 1mg/ml, 
Concentartion of Clonazepam : 20 µg /ml). 
Forced degradation studies  
Forced degradation studies were performed at a 1048 mg of 
paroxetine and clonazepam in capsules to provide an indication of 
the stability-indicating property and specificity of the proposed 
method. A peak purity test was conducted for paroxetine and 
clonazepam peaks by using a PDA detector on stress samples. All 
solutions used in forced degradation studies were prepared by 
dissolving the drug product in a small volume of stressing agents. 
After degradation, these solutions were diluted with mobile phase to 
yield a stated concentration approximately. Conditions employed for 
performing the stress studies are described below. 
Acid degradation 
Tablet powder equivalent to 1048 mg was accurately weighed and 
dissolved in 5 ml of mobile phase, 5 ml 5 N Hcl was added and the 
mixture was kept at 700
To prepare the blank, 5 ml of 5 N HCl and 5 ml of 5 N NaOH were 
diluted to 25 ml with mobile phase. 
C for 5 min. The solution was brought to 
ambient temperature, neutralized by the addition of 5 ml 5 N NaOH 
and diluted to 25 ml with mobile phase. 
Base degradation 
Tablet powder equivalent to 1048 mg was accurately weighed and 
dissolved in 5 ml of mobile phase, 5 ml 5N NaOH was added and the 
mixture was kept at 700C for 5 min. The solution was brought to 
ambient temperature, neutralized by the addition of 5 ml 5 N HCl 
and diluted to 25 ml with mobile phase. 
To prepare the blank, 5 ml of 5 N NaOH and 5 ml of 5 N HCl were 
diluted to 25 ml with mobile phase. 
Oxidation degradation 
Tablet powder equivalent to 1048 mg was accurately weighed and 
dissolved in 5 ml of mobile phase, 5 ml of 3% hydrogen peroxide 
was added and the mixture was kept at 700
 To prepare the blank, 5 ml of 3% hydrogen peroxide was diluted to 
25 ml with mobile phase. 
C for 10 min. The solution 
was brought to ambient temperature and diluted to 25 ml with 
mobile phase. 
Thermal degradation 
Tablet powder equivalent to 1048 mg was stored at 1050
Photolytic degradation  
C for 9 hr, 
dissolved and diluted to 25 mL with mobile phase. 
The susceptibility of the drug product to the light was studied. 
Tablet powder for photo stability testing was placed in a photo 
stability chamber and exposed to a white florescent lamp with an 
overall illumination of 1.2 million lux hours and near UV radiation 
with an overall illumination of 200 watt/m2/h at 250
RESULTS AND DISCUSSION 
C. Following 
removal from the photo stability chamber, the sample was prepared 
for analysis as previously described. 
Method Development 
The analytical procedure for the estimation of paroxetine and 
clonazepam in marketed formulation was optimized with a view to 
develop a precise and accurate assay method. Agilent Eclipse XDB 
(4.6*150mm*3.5mic), Agilent Zorbax C8 (4.6*150mm*5mic) and 
Inertsil-ODS (4.6*250mm*5mic) were used to provide an efficient 
separation but appropriate chromatographic separation was 
achieved on An Agilent zorbax sb-c18 (250mmx4.6mmx5mic). 
Various mobile phase systems were prepared and used to provide 
an appropriate chromatographic separation, but the proposed 
mobile phase containing 0.2% v/v Orthophoshoric acid: Methanol in 
the ratio of 60:40 (v/v) gave a better resolution. Using UV-visible 
PDA detector at 270 nm carried out the detection. Amongst the 
several flow rates tested, the flow rate of 1 ml/min was the best 
suited for both the drugs with respect to location and resolution of 
peaks. The retention time of paroxetine and clonazepam was found 
to 3.478min and 3.964 min respectively. The chromatograms of 
standard and sample solution of paroxetine and clonazepam were 
shown in Figure II. The asymmetry factor of paroxetine and 
clonazepam was 1.246 and 1.196 found to be respectively, which 
indicates symmetrical nature of the peak. The USP resolution of 
3.361was achieved between paroxetine and clonazepam. The USP 
plate count of paroxetine and clonazepam was 10704 and 11407 
found to be respectively, which indicates column efficiency for 
separation. System suitability parameters such as Peak asymmetry, 
Resolution and Number of theoretical plates are meeting ICH 
requirements. The percentage label claim of individual drugs found 
in formulations were calculated and provided in Table I. The results 
of analysis shows that the amounts of drugs estimated were in good 
agreement with the label claim of the formulations. 
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Fig. 2: Typical chromatograms of Paroxetine and Clonazepam 
(A) Standard (B) Formulation 
 
Table 1: Assay results 






claim (% w/w) 
Paroxetine 25 mg 24.79 99.1 
Clonazepam  0.5 mg 0.5 100 
 
Method Validation  
System Suitability Studies 
System suitability was determined before sample analysis from 
duplicate injections of the standard solutions of paroxetine and 
clonazepam.The column efficiency, resolution and peak asymmetry 
were calculated for the standard solutions. Resolution between 
paroxetine and clonazepam peaks was found to be 3.361. USP tailing 
(Peak Asymmetry) for paroxetine and clonazepam were found to be 
1.246 and 1.196 respectively. Number of theoretical plates (USP 
plate count) for paroxetine and clonazepam were found to be 10704 
and 11407 respectively. 
The values obtained demonstrated the suitability of the system for 
the analysis of this drug combinations, system suitability parameters 
may fall within ± 3 % standard deviation range during routine 
performance of the method. 
Specificity 
Specificity is the ability to assess unequivocally the analyte in 
presence of components which may be expected to be present. 
Typically these might include impurities, degradants, matrix, etc. 
Placebo interference was evaluated by analyzing the placebo 
prepared by the test method. No peak due to placebo was detected 
at the retention time of paroxetine and clonazepam. The specificity 
of the developed method was also conducted in presence of its 
degradation products. 
Precision 
The precision of method was verified by repeatability and 
intermediate precision. Repeatability was checked by injecting six 
individual sample preparations of paroxetine and clonazepam 
capsule. Percent relative standard deviation (RSD) of the area for 
each drug was calculated. The intermediate precision of the method 
was also evaluated using different analysts and different 
instruments and performing the analysis on different days. The 
results of precision study are provided in Table II.  
Accuracy 
The accuracy of the method was determined by recovery 
experiments. The recovery studies were evaluated in triplicate using 
three concentration levels 50%, 100% and 150%. The percentage 
recovery data was obtained, added recoveries of standard drugs 
were found to be accurate (Table III & IV). 
Linearity and Range  
The linearity of the method was determined at five concentration 
levels (50%, 75%, 100%, 125% and 150%). Linearity test solutions 
were prepared by diluting the stock solutions to the required 
concentrations. The calibration curves were plotted between the 
responses of peak area versus concentration of analyte. The slope 
and intercept value for calibration curve was y = 16616 x (r2=0.99) 
for paroxetine and y = 19288 x (r2=0.99) for clonazepam. The result 
(Table V) shows that an excellent correlation exists between areas 
and concentration of drugs within the concentration range. 
Calibration curves are presented in Figure III. 
Limit of detection & Limit of quantification (LOD & LOQ) 
Limit of quantification and detection were predicted by plotting 
linearity curve for different nominal concentrations of paroxetine 
and clonazepam (Table V).  
Relative standard deviation (σ) method was applied, the LOQ and 
LOD values were predicted using following formulas. Precision was 
established at these predicted levels. 
 (a) LOQ = 10 σ / S  
 (b) LOD = 3.3 σ / S  
Where σ = Residual standard deviation of response;  
 S = slope of the calibration curve. 
LOQ and LOD values for paroxetine and clonazepam were found to 
be 9.501, 8.064 and 2.850, 2.419 respectively. 
Robustness 
Robustness of the method was determined by making slight changes 
in the chromatographic conditions and system suitability 
parameters for paroxetine and clonazepam standard and the 
resolution, USP Tailing and USP Plate count were recorded. The 
variables evaluated in the study were column temperature (±50
 
C), 
flow rate (±0.2 mL/min). It was observed that there were no marked 
changes in the chromatograms, which demonstrates that the method 
developed is rugged and robust (Table VI & VII) 
   
Fig. 3: Linearity graphs of Paroxetine and Clonazepam 
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Table 2: Precision Studies of Paroxetine and Clonazepam 
S. No. Sample Wt Area of Paroxetine Area of Clonazepam % Assay of Paroxetine % Assay of Clonazepam 
1 1047.84 2329638 2244561 99 100 
2 1047.84 2327634 2249193 99 100 
3 1047.84 2320550 2248507 99 100 
4 1047.84 2322042 2247725 99 100 
5 1047.84 2321371 2244102 99 100 
6 1047.84 2325815 2241087 99 99 
Average 99 100 
STD 3725.18 3135.38 
%RSD 0.16 0.14 
 
Table 3: Accuracy for Paroxetine 
Spiked Level Sample Weight Sample Area µg/ml added µg/ml found % Recovery Mean 
50% 523.92 1164679 198.000 198.59 100 100 
50% 523.92 1161393 198.000 198.03 100 
50% 523.92 1163728 198.000 198.42 100 100 
100% 1047.84 2328234 396.000 396.98 100 
100% 1047.84 2324841 396.000 396.40 100 
100% 1047.84 2322363 396.000 395.98 100 100 
150% 1571.76 3486485 594.000 594.47 100 
150% 1571.76 3485959 594.000 594.38 100 
 
Table 4: Accuracy of Clonazepam 
Spiked level Sample weight Sample Area µg/ml added µg/ml found % Recovery Mean 
50% 523.92 1124728 4.00 3.99 100 100 
50% 523.92 1127607 4.00 4.00 100 
50% 523.92 1128025 4.00 4.00 100 
100% 1047.84 2244332.00 8.00 7.96 100 100 
100% 1047.84 2244473.00 8.00 7.96 100 
100% 1047.84 2241524.00 8.00 7.95 99 
150% 1571.76 3374707 12.00 11.98 100 100 
150% 1571.76 3374280 12.00 11.97 100 
150% 1571.76 3377070 12.00 11.98 100 
 
Table 5: Linearity of Paroxetine and Clonazepam 
Paroxetine Clonazepam 
% Conc. Area ug/ml LOD LOQ % Conc. Area ug/ml LOD LOQ 
50 1165038 200 S/N 421 50 1128876 4 S/N 9.92 
75 1742669 300 2.850 9.501 75 1681221 6 2.419 8.064 
100 2324454 400 100 2240026 8 
125 2908660 500 125 2808149 10 
150 3483836 600 150 3373098 12 
 
Table 6: Robustness of Paroxetine 
Sample Name RT Area USP Tailing USP Plate count S/N 
TEMP-1 1 3.485 2353377 1.223 10195 
TEMP-2 1 3.453 2305010 1.169 10854 
FLOW-1 1 4.634 3134093 1.271 11944 
FLOW-2 1 2.797 1903663 1.198 8117 
 
Table 7: Robustness of Clonazepam 
Sample Name RT Area USP Tailing USP Plate count S/N 
TEMP-1 3.897 7425147 1.177 7989 635.11 
TEMP-2 3.802 6964485 1.174 8811 670.73 
FLOW-1 4.548 10059395 1.171 8911 816.17 
FLOW-2 3.433 7024245 1.193 7317 688.34 
 
Forced Degradation Studies  
Based on the results of the stress studies, the degradation behavior 
of paroxetine and clonazepam is as follows. 
Acid degradation 
Paroxetine and Clonazepam were undergoing degradation in 5 N HCl 
at 700C for 10 min moderately. The impurities formed during this 
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study are well separated from main drug peaks and mass balance is 
found to be in acceptable limit. Peak purity of drugs also matches 
(Table VIII, Figure IV (A). 
Base degradation  
Paroxetine and Clonazepam were found to be slightly unstable in 5 N 
NaOH at 700C for 5 min. The major degradation peaks are well 
separated from drug peaks and well resolved. Mass balance is found 
to be in acceptable limit. Peak purity of drugs also matches (Table 
VIII, Figure IV (B). 
Oxidation degradation  
Paroxetine and Clonazepam were found to be slightly unstable 
under conditions of 3% hydrogen peroxide at 700
Thermal degradation 
C for 10 min. The 
major impurities in the study were resolved with drug peaks. Mass 
balance is found to be in acceptable limit. Peak purity of drugs also 
matches (Table VIII, Figure IV (C). 
Paroxetine and Clonazepam were found to be stable to thermal 
exposure. Partial degradation was take place. Impurities formed well 
resolved from main drug peaks. Mass balance is found to be in 
acceptable limit. Peak purity of drugs also matches (Table VIII, 
Figure IV (D). 
Photolytic degradation 
Upon subjecting the Paroxetine and Clonazepam sample to both UV 
and visible light, only partial degradation of sample was observed.  
Testing of a placebo containing preservative leads to formation of 
number of different impurities with respect to an unstressed 
placebo. The amount of preservative decreased mainly by influence 
of oxidation, light and acid. Mass balance of preservative shows 
almost 100%. The active ingredients remain almost stable within 
tested period and mass balance matches (Table VIII, Figure IV (E). 
  
Table 8: Degradation studies for Paroxetine and Clonazepam 
Stress condition Sample weight Paroxetine Clonazepam 
Area % Assay % Deg. Area % Assay % Deg. 
Acid 1048 2028376 86 -13 1885379 84 -16 
Base 1048 2096111 89 -10 1884672 84 -16 
Peroxide 1048 2112722 90 -9 1967354 88 -12 
Heat 1048 2197396 94 -5 2185996 97 -3 
Light 1048 2155038 92 -7 2085936 93 -7 
 
 




The The proposed HPLC method for the simultaneous estimation of 
paroxetine and clonazepam in pharmaceutical dosage forms was 
found to be simple, sensitive, precise, accurate, linear, robust and 
rugged during validation. Further this method is stability indicating 
and can be used for routine analysis of production samples. Hence, 
this method can be easily and conveniently adopt for routine quality 
control of paroxetine and clonazepam in pure and its pharmaceutical 
dosage forms. 
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